• Stuart J. Swiedler, M.D., Ph.D.


    Dr. Swiedler is a biotechnology consultant with more than 20 years of experience in the biotechnology field, primarily as a scientist and junior executive at Glycomed, Inc., and as a clinical scientist and senior executive at BioMarin Pharmaceutical, Inc. Over a 10-year period at BioMarin, he contributed to both the non-clinical and clinical aspects of drug development for the regulatory approvals of the orphan drugs Aldurazyme, Naglazyme and Kuvan. He continues to focus on orphan drug products for genetic diseases, working with both biotech companies and investment firms. He received his Bachelor of Science degree from the University at Albany, and his M.D. and Ph.D. degrees from the Johns Hopkins University School of Medicine. He completed a residency program in Anatomic Pathology at Yale University School of Medicine and Duke University School of Medicine, and a post-doctoral fellowship at Duke.

  • William M. Pardridge, M.D.

    Founder and Chief Scientific Officer

    Dr. Pardridge formed ArmaGen in 2003 and supported the company the first 10 years with $20 million in non-dilutive funding. Dr. Pardridge, who is a Distinguished Professor Emeritus, UCLA, is a recognized leader in blood brain barrier (BBB) research. He has focused on the area since 1970, and is credited with inventing antibody directed receptor-mediated transcytosis technology, the liposome technology for non-viral, non-invasive gene therapy of the brain, and the field of BBB genomics. He is the author of over 500 publications, more than 45 of which focus on the BBB. Dr. Pardridge is board certified in Internal Medicine, and Endocrinology and Metabolism.

  • James E. Callaway, Ph.D.

    Chief Executive Officer of ArmaGen

    Dr. Callaway has 30 years of biopharmaceutical experience, during which he has filed and defended numerous NDAs and INDs. Before joining ArmaGen in December 2012, he served as President and CEO of Cebix Inc., a biopharmaceutical company focused on the treatment of long-term complications of diabetes. Prior to that, he filled several executive roles during his thirteen-year tenure at Elan Pharmaceutical, including Program Executive for the Alzheimer’s Immunotherapy program encompassing five pipeline candidates including bapinuzumab, and Vice President Biopharmaceutical Development Services. During his tenure at Elan, he led the approval of MyoBloc® and the production of Tysabri®. Prior to Elan, Dr. Callaway held development responsibilities at Bayer Pharmaceuticals, SmithKline Beecham (GSK) as well as Ingene (Xoma). Dr. Callaway received his Ph.D. in biological chemistry from UCLA with a focus on peptide chemistry.

  • Martin Heidecker, Ph.D.

    Boehringer Ingelheim Venture Fund (BIVF)

    Dr. Heidecker has 15 years of investment and commercial experience with venture capital and global pharmaceutical companies. He established the U.S.-office of Boehringer Ingelheim Venture Fund (BIVF) where he is focusing on biotech seed-investments. He previously held Senior Business Analyst and Director roles within the Global Business Analysis department, providing strategic marketing support for CNS, Women’s Health and Oncology. Prior to joining Boehringer Ingelheim (BI), Martin held several positions within the global Business Intelligence Department of Solvay Pharmaceuticals, focusing primarily on compounds in early clinical stages. Before Solvay, Martin was an investment manager at Bayern Kapital. During this time, he led co-investments in early stage drug development, medical devices, and bioinformatic companies. Dr. Heidecker holds a Ph.D. in Biology, focusing on membrane transport proteins in his thesis. He also has a Master’s degree in Biology and Economics.

  • Deanna Petersen, MBA

    VP, Business Development, Shire Pharmaceuticals, LLC.

    Ms. Petersen is a broadly skilled senior executive with 20 years of leadership experience in global business development. She joined Shire in 2009 as Vice President of Business Development and now heads up all business development activity for the rare disease business unit and new therapeutic areas that are growth opportunities for the company. Ms. Petersen and her team are responsible for identifying and evaluating new business opportunities, and for negotiating all types of transactions including acquisitions (public and private), licenses and other partnerships and collaborations. Prior to joining Shire, Ms. Petersen was Vice President of Business Development at Agenus Inc. and at Coley Pharmaceutical Group, and was on the senior leadership teams of each. Ms. Petersen is on the Board of Directors for American DG Energy and for the Massachusetts Biotechnology Association, and was formerly on the Board of Directors for the Healthcare Businesswomen’s Association, Boston Chapter. Ms. Petersen holds a Bachelor of Science in Biology from Iowa State University and a Master of Business Administration from The University of Iowa.

  • Michael Martin, Ph.D. (Observer)

    Senior Investment Director with Takeda Ventures, Inc. (TVI), the corporate venture arm of Takeda Pharmaceutical Company, Ltd.

    Dr. Michael Martin is a Senior Investment Director with Takeda Ventures, Inc. (TVI) and he is based in San Diego, CA. His professional background includes venture capital, pharma business development and broad R&D experiences with an integral role in the discovery and preclinical/clinical development of 17 innovative investigational drugs and 2 commercial products. Prior to joining TVI, Dr. Martin was most recently a member of Global Licensing and Business Development at Takeda, heading efforts for sourcing and transacting technologies and early stage pipeline programs. Dr. Martin joined Takeda in January 2012 through the acquisition of Intellikine where he was Vice President of Preclinical Development. Additionally, he has held executive and senior management and scientific positions with TargeGen (acquired by Sanofi-Aventis), Arena Pharmaceuticals, and Monsanto Corporation. Dr. Martin earned his doctorate in Medicinal Chemistry from the University of Illinois and holds a M.S. degree in analytical chemistry and B.S. degrees in Chemistry and Mathematics.

  • Mutsuki Takano (Observer)

    Investment Director at Mitsui & Company Global Investment, Inc. (MGI)

    Investment Director at Mitsui & Company Global Investment, Inc. (MGI)
    Mr. Takano joined Mitsui & Co., Ltd. in 2004. After 2 of years training in the accounting and risk management team, he moved to the Ship and Marine Project Div where he played a role in the business development of long-term package deals in the shipbuilding industry with owners, operators, charterers and manufacturers. In 2008, he was deployed to China to restructure the growth strategy for the company in China. Two years later he moved back to the Principal Investment Division in Tokyo and assumed a position on the incubation project team. There he led a new joint venture establishment with the world’s largest engineering company, to build a multinational consortium of EV bus experimental operations together with an induction charge system in the UK. In November 2013, after returning to the back-office to work in portfolio management, he joined the biotech team in US.